Microbix BiosystemsTSX:MBX -3.28%52 Gross Margin % is 48.19% as of Mar. 2026, which is 5% below its 10-year median of 50.57. GuruFocus rates TSX:MBX with a GF Score™ of 52/100 and a GF Value™ of C$0.24 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 737 Biotechnology companies, Microbix Biosystems ranks worse than 67.16% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Microbix Biosystems had a gross margin of 48.19% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Microbix Biosystems Gross Margin % Related Terms
Microbix Biosystems Gross Margin % Historical Data
* Premium members only.
The historical data trend for Microbix Biosystems's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:MBX vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Microbix Biosystems's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Microbix Biosystems (TSX:MBX) has a Gross Margin % of 48.19% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Microbix Biosystems and its competitors. This is near median its historical median of 50.57. Over the past decade, Microbix Biosystems' Gross Margin % has ranged from 42.48 to 60.61. According to the industry distribution chart, Microbix Biosystems ranks #495 out of 737 companies in the Biotechnology industry, placing it in the top 67.2%.
Is Microbix Biosystems' Gross Margin % too high?
Microbix Biosystems' current Gross Margin % of 48.19% is near median its 10-year median of 50.57. Over the past 10 years, this metric has ranged from a low of 42.48 to a high of 60.61. The Biotechnology industry median Gross Margin % is 60.92. Microbix Biosystems' value of 48.19% is 20.9% below this industry median. Based on the distribution chart, Microbix Biosystems ranks #495 out of 737 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Microbix Biosystems has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #495 out of 737 companies for Gross Margin %. This places Microbix Biosystems in the lower half of its industry. The industry median Gross Margin % is 60.92. Microbix Biosystems' value of 48.19% is 20.9% below this benchmark. Historically, Microbix Biosystems' own Gross Margin % has ranged from 42.48 to 60.61 over the past decade. While the company's 10-year median is 50.57 vs. the industry median of 60.92, Microbix Biosystems has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microbix Biosystems's current Gross Margin % of 48.19% is 20.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Microbix Biosystems and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microbix Biosystems's current Gross Margin % is 48.19%, which is near median its own 10-year median of 50.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (TSX:MBX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.24, compared to a current price of C$0.30 — trading 22.9% above its estimated fair value. The current Gross Margin % is 48.19%, which is near median its 10-year median of 50.57 and 20.9% below the Biotechnology industry median of 60.92. Microbix Biosystems' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Microbix Biosystems (TSX:MBX), the current Gross Margin % is 48.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (TSX:MBX) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of C$0.30 is trading 22.9% above its estimated GF Value™ of C$0.24.
GuruFocus considers Microbix Biosystems to be Modestly Overvalued.
Key valuation signals for TSX:MBX:
Gross Margin %: 48.19% (near median its 10-year median of 50.57)
GF Value™: C$0.24 vs. price of C$0.30 (22.9% above fair value)
Industry Position: 20.9% below the Biotechnology median (#495 of 737)
No single metric tells the full story. See the TSX:MBX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
52GF Score
Get the complete analysis for TSX:MBX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MBX has been successfully added to your 
